MLYS Mineralys Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1933414 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-115.9%
TTM EPS YoY-47.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-68.5%
ROA-60.2%
ROIC (approx.)-80.9%
Asset turnover—
Leverage & solvency
Liabilities / assets20.1%
Debt / equity0.00x
Current ratio11.83x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.41x
Accruals ratio-35.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $22.67M | $221.38M | $24.36M | $24.40M | $31.45M | $38.28M | $37.88M | $44.57M |
| SG&A expense | $37.42M | $24.66M | $20.98M | $13.88M | $9.68M | $8.47M | $6.57M | $7.20M |
| Operating income | -$60.09M | -$246.04M | -$45.34M | -$38.28M | -$41.13M | -$46.75M | -$44.45M | -$51.77M |
| Interest expense | $3.19M | — | — | — | $0 | — | — | — |
| Income tax | — | — | — | $0 | — | — | — | — |
| Net income | -$57.33M | -$241.07M | -$39.34M | -$32.23M | -$36.93M | -$43.27M | -$42.21M | -$48.95M |
| EBITDA | -$60.08M | -$246.03M | -$45.33M | -$38.27M | -$41.12M | -$46.73M | -$44.43M | -$51.75M |
| EPS (basic) | -0.64 | -2.85 | -0.47 | — | -0.52 | -0.66 | -0.79 | — |
| EPS (diluted) | -0.64 | -2.85 | -0.47 | — | -0.52 | -0.66 | -0.79 | — |
| Weighted avg. shares (diluted) | 88.99M | 84.73M | 82.83M | — | 70.59M | 65.45M | 53.16M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $101.27M | $138.27M | $112.78M | $172.92M | $217.60M | $101.79M | $165.01M | $114.09M |
| Current assets | $627.99M | $665.80M | $652.47M | $661.39M | $599.80M | $335.27M | $354.51M | $205.35M |
| PP&E, net | $21,000 | $27,000 | $32,000 | $38,000 | $7,000 | $22,000 | $38,000 | $53,000 |
| Total assets | $630.12M | $667.85M | $652.86M | $661.81M | $599.95M | $335.72M | $354.94M | $205.90M |
| Current liabilities | $53.08M | $19.32M | $14.72M | $15.11M | $23.52M | $22.17M | $13.39M | $14.65M |
| Long-term debt | $100,000 | $100,000 | — | — | — | — | — | — |
| Total debt | $100,000 | $100,000 | — | — | — | — | — | — |
| Total liabilities | $126.35M | $116.94M | $14.72M | $15.11M | $23.52M | $22.17M | $13.39M | $14.65M |
| Shareholders' equity | $503.77M | $550.92M | $638.14M | $646.69M | $576.43M | $313.55M | $341.56M | $191.26M |
| Net debt | -$101.17M | -$138.17M | — | — | — | — | — | — |
| Shares outstanding | 88.53M | 88.35M | 82.45M | 81.54M | 78.97M | 65.73M | 64.88M | 49.82M |
| Cash flow statement | ||||||||
| Operating cash flow | -$43.10M | -$32.56M | -$39.47M | -$37.89M | -$28.87M | -$30.17M | -$45.49M | -$66.84M |
| Capital expenditure | — | — | — | $15,000 | $0 | $0 | $0 | $0 |
| Free cash flow | — | — | — | -$37.90M | -$28.87M | -$30.17M | -$45.49M | -$66.84M |
| Investing cash flow | $4.70M | -$185.22M | -$44.94M | -$103.49M | -$150.51M | -$42.88M | -$92.88M | $83.57M |
| Financing cash flow | $1.40M | $243.26M | $24.27M | $96.70M | $295.19M | $9.83M | $189.28M | $90,000 |
| Depreciation & amortization | $6,000 | $5,000 | $6,000 | $13,000 | $15,000 | $16,000 | $15,000 | $15,000 |
| Stock-based compensation | $7.88M | $7.36M | $6.55M | $5.29M | $5.84M | $4.55M | $3.65M | $3.13M |
Free plan shows the latest 8 periods; Pro shows all 19 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.